Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
HNSCC
Nectin-4
enfortumab-vedotin
p16
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
20 10 2022
20 10 2022
Historique:
entrez:
21
10
2022
pubmed:
22
10
2022
medline:
25
10
2022
Statut:
epublish
Résumé
Nectin-4 has been successfully established as a target molecule in locally advanced and metastatic bladder cancer. An antibody-drug conjugate (enfortumab-vedotin) directed against nectin-4 has shown marked tumor remission rates in this tumor type, which is known for high expression rates of nectin-4. As head and neck cancer and urothelial carcinomas share morphological and molecular similarities, we aimed to evaluate Nectin-4 expression in head and neck squamous cell carcinoma (HNSCC). A previously described and clinically characterized cohort of HNSCC ( Nectin-4 was found in 86.2% of HNSCC, with medium/high expression seen in 32.7% of cases. Non smokers and p16 positive HNSCC showed a higher expression of Nectin-4 ( Similar to urothelial carcinoma, Nectin-4 is found in the majority of HNSCC, which clearly warrants further studies to clarify if HNSCC also respond to targeted therapy with enfortumab-vedotin. Moreover, expression of Nectin-4 is associated with HPV infection and may serve as a prognostic marker in HNSCC.
Identifiants
pubmed: 36268557
pii: 28299
doi: 10.18632/oncotarget.28299
pmc: PMC9584426
doi:
Substances chimiques
Cell Adhesion Molecules
0
Immunoconjugates
0
Nectins
0
NECTIN4 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1166-1173Références
Head Neck. 2020 Apr;42(4):774-786
pubmed: 31762164
J Cell Sci. 2012 Aug 15;125(Pt 16):3713-22
pubmed: 23027581
Ther Adv Urol. 2020 Dec 27;12:1756287220980192
pubmed: 33447264
Curr Oncol Rep. 2018 Mar 3;20(2):22
pubmed: 29502288
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
J Clin Oncol. 2020 Apr 1;38(10):1041-1049
pubmed: 32031899
Aust Dent J. 2019 Mar;64(1):11-18
pubmed: 30238467
Biomedicines. 2021 Mar 30;9(4):
pubmed: 33808400
Pharmaceuticals (Basel). 2021 Feb 28;14(3):
pubmed: 33670993
Drugs. 2020 Jan;80(1):1-7
pubmed: 31823332
J Biol Chem. 2002 Jul 26;277(30):27006-13
pubmed: 12011057
Front Med (Lausanne). 2019 Sep 13;6:200
pubmed: 31572728
Oncogene. 2015 Sep 10;34(37):4845-54
pubmed: 25500544
Ann Oncol. 2017 Apr 1;28(4):769-776
pubmed: 27998973
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
J Biol Chem. 2001 Nov 16;276(46):43205-15
pubmed: 11544254
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32503945
Nat Rev Mol Cell Biol. 2008 Aug;9(8):603-15
pubmed: 18648374
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Nat Rev Urol. 2021 Feb;18(2):93-103
pubmed: 33239713
Lancet. 2008 May 17;371(9625):1695-709
pubmed: 18486742
Front Oncol. 2021 Mar 04;11:621591
pubmed: 33747934
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
Oncotarget. 2017 May 2;8(32):52889-52900
pubmed: 28881780
Am J Clin Pathol. 2010 Nov;134(5):835-45
pubmed: 20959669
Int J Mol Sci. 2020 Jul 29;21(15):
pubmed: 32751328
Clin Cancer Res. 2015 Feb 1;21(3):632-41
pubmed: 25056374
Head Neck. 2019 Oct;41 Suppl 1:4-18
pubmed: 31573752
Cancer Res. 2016 May 15;76(10):3003-13
pubmed: 27013195
Med Sci Monit. 2019 Dec 28;25:10089-10094
pubmed: 31883369
Ann Oncol. 2017 Jul 01;28(7):1605-1611
pubmed: 28419181
Oncotarget. 2017 Feb 7;8(6):9717-9738
pubmed: 28038455
Oncol Lett. 2018 Jun;15(6):8789-8795
pubmed: 29805618
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140